Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93
- 168 Downloads
To compare the efficacy of chemoendocrine treatment with that of endocrine treatment (ET) alone for postmenopausal women with highly endocrine responsive breast cancer. In the International Breast Cancer Study Group (IBCSG) Trials VII and 12–93, postmenopausal women with node-positive, estrogen receptor (ER)-positive or ER-negative, operable breast cancer were randomized to receive either chemotherapy or endocrine therapy or combined chemoendocrine treatment. Results were analyzed overall in the cohort of 893 patients with endocrine-responsive disease, and according to prospectively defined categories of ER, age and nodal status. STEPP analyses assessed chemotherapy effect. The median follow-up was 13 years. Adding chemotherapy reduced the relative risk of a disease-free survival event by 19% (P = 0.02) compared with ET alone. STEPP analyses showed little effect of chemotherapy for tumors with high levels of ER expression (P = 0.07), or for the cohort with one positive node (P = 0.03). Chemotherapy significantly improves disease-free survival for postmenopausal women with endocrine-responsive breast cancer, but the magnitude of the effect is substantially attenuated if ER levels are high.
KeywordsBreast cancer Chemoendocrine therapy Estrogen receptors Postmenopausal
We thank the patients, physicians, nurses, and data managers who have participated in the International Breast Cancer Study Group (see Appendix) trials, now and for the past 30 years. The IBCSG is funded in part by: Swiss Group for Clinical Cancer Research (SAKK), Frontier Science and Technology Research Foundation (FSTRF), The Cancer Council Australia, Australian New Zealand Breast Cancer Trials Group (National Health Medical Research Council), National Cancer Institute (CA-75362), Swedish Cancer Society, Cancer Research Switzerland/Oncosuisse, Cancer Association of South Africa, Foundation for Clinical Cancer Research of Eastern Switzerland (OSKK).
- 6.Namer M, Fargeot P, Roché H et al (2006) Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials. Ann Oncol 17:65–73. doi: 10.1093/annonc/mdj022 PubMedCrossRefGoogle Scholar
- 10.Albain K, Barlow W, O’Malley F et al (2004) Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat 88:(abstr 37)Google Scholar
- 11.The International Breast Cancer Study Group (1997) Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 15:1385–1393Google Scholar
- 15.Greenwood M (1926) The natural duration of cancer. Her Majesty’s Stationary Office, London, pp 1–26Google Scholar
- 17.Cox DR (1972) Regression models and life-tables (with discussion). J R Stat Soc [Ser A] 34:187–220Google Scholar
- 24.Coates AS, Keshaviah A, Thürlimann B et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol 25:486–492. doi: 10.1200/JCO.2006.08.8617 PubMedCrossRefGoogle Scholar
- 26.Viale G, Regan MM, Maiorano E et al (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:BIG 1–98. J Clin Oncol 25:3846–3852. doi: 10.1200/JCO.2007.11.9453 PubMedCrossRefGoogle Scholar
- 29.Albain K, Barlow W, Shak S et al (2008) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100). San Antonio breast cancer symposium 2007 late breaker abstract #10 http://www.abstracts2view.com/sabcs/view.php?nu=SABCS07L_1165. Accessed 02 Jan 2008
- 32.Thürlimann B, Price KN, Gelber RD et al (2008) Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11–93. Breast Cancer Res Treat 2008(Feb):8 (Epub ahead of press)Google Scholar